Patrick Rial of TriVista Capital presented his in-depth investment thesis on Kitazato Corporation (Japan: 368A) at Asian Investing Summit 2026.
Thesis summary:
Kitazato is Japan’s leading provider of consumables for in vitro fertilization (IVF), generating over 60% of sales internationally and posting a 56% operating margin — the sixth-highest among non-financial Japanese listings. Patrick estimates the global fertility treatment market at roughly $49 billion, with 5-8% expected growth driven by later marriage, declining male sperm counts, rising egg-freezing adoption, expanding insurance coverage, and ongoing technological improvement. Kitazato’s sales have compounded at an 8.9% CAGR over the last decade.
The company’s moat stems from the vitrification revolution it pioneered with Japan’s Kato Ladies Clinic around 2000. Vitrification flash-freezes eggs in a glass-like state using liquid nitrogen, eliminating the ice-crystal damage of slow freezing and enabling near-100% thaw survival. Industry adoption from 2005 made it the global standard of care. Roughly 65% of Kitazato’s sales tie to vitrification, where it holds 60% share in Japan, 70% in Europe, 80% in China, and 85% in India. Across Japanese product categories, share ranges from 50% to 96%, including a near-monopoly in Cryotop storage devices.
Patrick views founder Futoshi Inoue, 55, as an exceptional operator aligned with shareholders. Inoue owns 58.9% of the company, describes shareholders as co-managers, and is unhappy with post-IPO share performance. FY results due in May should beat a -7.1% operating profit guide (Patrick models +4.5%); a dividend payout lift from the current 40% toward 50-70% is plausible given ¥12 billion of net cash and minimal capex; a potential cryobank business could open a new profit pool; and US growth should accelerate under new distribution partner DeviMed. Principal risks include competition, technological disruption, margin compression, and a possible further stake sale by Inoue.
The shares recently traded at 6.9x EV/EBIT, 13.3x P/E, 2.77x P/B, and a 3.0% dividend yield, with a ¥53 billion market cap. Public peers Cooper Companies and Vitrolife trade at 17.7-23.5x EV/EBIT and 24-38x P/E despite lower margins, while recent industry M&A has taken place at 5x+ sales, implying 18x+ EBITDA. Patrick’s DCF, assuming 4-8% sales growth and 57-59% operating margins, yields a ¥1,387-¥2,238 fair value range.
Disclaimer
Asian Investing Summit 2026 was held from April 14-21, 2026. The content of this website is not an offer to sell or the solicitation of an offer to buy any security. The content is distributed for informational purposes only and should not be construed as investment advice or a recommendation to sell or buy any security or other investment, or undertake any investment strategy. There are no warranties, expressed or implied, as to the accuracy, completeness, or results obtained from any information set forth on this website. BeyondProxy’s officers, directors, employees, and/or contributing authors may have positions in and may, from time to time, make purchases or sales of the securities or other investments discussed or evaluated herein.
Slides
Let’s take a closer look.
